Sigma Planning Corp Medicenna Therapeutics Corp. Transaction History

Sigma Planning Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 06, 2023	BUY	$0.28 - $0.51 $92,190 - $167,917	329,250 Added 107.84%	634,550 $190,000
Q2 2023 Aug 01, 2023	BUY	$0.44 - $0.82 $1,430 - $2,665	3,250 Added 1.08%	305,300 $146,000
Q1 2023 May 05, 2023	SELL	$0.5 - $0.78 $250 - $390	-500 Reduced 0.17%	302,050 $190,000
Q4 2022 Jan 24, 2023	BUY	$0.4 - $0.68 $15,800 - $26,860	39,500 Added 15.02%	302,550 $0
Q3 2022 Nov 10, 2022	BUY	$0.83 - $1.78 $9,130 - $19,580	11,000 Added 4.36%	263,050 $218,000
Q2 2022 Aug 11, 2022	BUY	$0.79 - $1.32 $40,882 - $68,310	51,750 Added 25.84%	252,050 $292,000
Q1 2022 Apr 20, 2022	BUY	$1.26 - $1.92 $75,915 - $115,680	60,250 Added 43.02%	200,300 $256,000
Q4 2021 Feb 02, 2022	BUY	$1.53 - $2.85 $167,611 - $312,217	109,550 Added 359.18%	140,050 $228,000
Q3 2021 Oct 28, 2021	BUY	$1.91 - $3.05 $58,255 - $93,025	30,500 New	30,500 $84,000

863K

Ticker MDNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,637,504
Market Cap $21.6M
Description
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as...

Get notified when there are updates to the investment portfolio of Sigma Planning Corp, based on Form 13F filings with the SEC.

Stay updated on Sigma Planning Corp with notifications on news.